| Dr Craig T Meisner, DO | |
|
1000 Harrington St, Mount Clemens, MI 48043-2920 | |
| (586) 493-8000 | |
| Not Available |
| Full Name | Dr Craig T Meisner |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 11 Years |
| Location | 1000 Harrington St, Mount Clemens, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235579467 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 5101020635 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Mercy Oakland | Pontiac, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Independent Emergency Physicians, P.c. | 6709798325 | 43 |
News Archive
The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.
Angiotech Pharmaceuticals, today announced that its Board of Directors has authorized the Company and certain of its subsidiaries to voluntarily file under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction.
The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).
The latest comeback in the health arena is whooping cough and experts are sufficiently concerned for the US government to approve the first whooping cough booster shot meant just for adolescents. The shot will be added to a booster shot against two other diseases, tetanus and diphtheria, that children already get sometime between ages 10 and 18.
› Verified 9 days ago
| Entity Name | Independent Emergency Physicians, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780791343 PECOS PAC ID: 6709798325 Enrollment ID: O20031103000407 |
News Archive
The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.
Angiotech Pharmaceuticals, today announced that its Board of Directors has authorized the Company and certain of its subsidiaries to voluntarily file under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction.
The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).
The latest comeback in the health arena is whooping cough and experts are sufficiently concerned for the US government to approve the first whooping cough booster shot meant just for adolescents. The shot will be added to a booster shot against two other diseases, tetanus and diphtheria, that children already get sometime between ages 10 and 18.
› Verified 9 days ago
| Entity Name | Independent Observation Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700119500 PECOS PAC ID: 3577603604 Enrollment ID: O20091221000327 |
News Archive
The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.
Angiotech Pharmaceuticals, today announced that its Board of Directors has authorized the Company and certain of its subsidiaries to voluntarily file under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction.
The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).
The latest comeback in the health arena is whooping cough and experts are sufficiently concerned for the US government to approve the first whooping cough booster shot meant just for adolescents. The shot will be added to a booster shot against two other diseases, tetanus and diphtheria, that children already get sometime between ages 10 and 18.
› Verified 9 days ago
| Entity Name | Ieppc Urgent Care Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689235897 PECOS PAC ID: 9032448766 Enrollment ID: O20190905002667 |
News Archive
The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.
Angiotech Pharmaceuticals, today announced that its Board of Directors has authorized the Company and certain of its subsidiaries to voluntarily file under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction.
The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).
The latest comeback in the health arena is whooping cough and experts are sufficiently concerned for the US government to approve the first whooping cough booster shot meant just for adolescents. The shot will be added to a booster shot against two other diseases, tetanus and diphtheria, that children already get sometime between ages 10 and 18.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Craig T Meisner, DO 1000 Harrington St, Mount Clemens, MI 48043-2920 Ph: (586) 493-8000 | Dr Craig T Meisner, DO 1000 Harrington St, Mount Clemens, MI 48043-2920 Ph: (586) 493-8000 |
News Archive
The deadline for approval or rejection of new drugs by the Food and Drug Administration (FDA) could be extended by two months say U.S. regulators and drug industry officials.
Angiotech Pharmaceuticals, today announced that its Board of Directors has authorized the Company and certain of its subsidiaries to voluntarily file under the Companies' Creditors Arrangement Act in order to continue implementation of its previously announced recapitalization transaction.
The AIDS Clinical Trials Group, the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401).
The latest comeback in the health arena is whooping cough and experts are sufficiently concerned for the US government to approve the first whooping cough booster shot meant just for adolescents. The shot will be added to a booster shot against two other diseases, tetanus and diphtheria, that children already get sometime between ages 10 and 18.
› Verified 9 days ago
Rebecca Marquis, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Harrington St, Mount Clemens, MI 48043 Phone: 586-493-8142 Fax: 586-493-3250 | |
Laura Hintze, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Harrington St, Mount Clemens, MI 48043 Phone: 586-790-9003 | |
Dr. Benjamin Jack Doerr, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Harrington St, Mount Clemens, MI 48043 Phone: 586-493-8000 | |
Peter Siclari, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Harrington St, Mount Clemens, MI 48043 Phone: 586-790-9003 | |
Eugene C Yen, D.O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Harrington St, Mount Clemens, MI 48043 Phone: 586-493-8000 | |
Joseph Nino Carlier, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1000 Harrington St, Mount Clemens, MI 48043 Phone: 586-493-8000 | |
Megan Maureen Mcgreevy, D. O. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1000 Harrington St, Mount Clemens, MI 48043 Phone: 586-493-8000 |